Injective CEO Eric Chen recently met with officials from the White House, the Securities and Exchange Commission, and the Commodity Futures Trading Commission to advance regulated onchain finance in the United States. The meetings took place in October 2026 with other Injective leadership present. The company has not disclosed specific outcomes from the meetings.
Injective's Regulatory Credentials
Injective arrived at the discussions with credentials uncommon among crypto projects. In August 2026, the SEC registered the company as a transfer agent, a role that involves maintaining official records of security ownership. This status allows Injective to keep ownership records for tokenized securities—the infrastructure institutional players require before moving significant capital onchain.
The company highlighted activity on its network, reporting over $1 billion in tokenized real-world asset value onchain and cumulative RWA perpetual trading volume exceeding $5.3 billion across asset classes including equities and commodities.
A Year of Regulatory Progress
Injective's recent meetings reflect broader momentum in the regulatory landscape. In 2025, the company proposed a time-based exemption for decentralized finance projects to develop before facing full securities compliance. The SEC introduced its Innovation Exemption in September 2026, signaling increased willingness to accommodate new financial technologies.
The company also secured a derivatives milestone when INJ futures launched on CFTC-regulated U.S. markets in late 2026, placing the token among a small group of digital assets with regulated derivatives access in the country.
Implications for Institutional Adoption
While Injective has not announced new regulatory approvals from the recent meetings, a clearer regulatory framework could reduce perceived risk for institutional participation in DeFi markets. Institutions typically avoid platforms without established legal footing.
The company's reported onchain figures—including the $1 billion in tokenized RWA value and $5.3 billion in cumulative perpetual volume—are company-reported numbers. Regulatory momentum can shift, and no meeting guarantees favorable outcomes. The practical impact of the SEC's Innovation Exemption will depend on which projects qualify and under what terms.
